4.4 Article

Type 2 diabetes mellitus and osteoarthritis

期刊

SEMINARS IN ARTHRITIS AND RHEUMATISM
卷 49, 期 1, 页码 9-19

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semarthrit.2019.01.005

关键词

Type 2 diabetes mellitus; Osteoarthritis; Obesity; Pathophysiology; Safety

资金

  1. ESCEO, a Belgian not-for-profit organization
  2. Chair for Biomarkers of Chronic Diseases
  3. International Scientific Partnership Program (ISPP) at King Saud University, Riyadh, Saudi Arabia [0111]
  4. MRC [MC_U147585819, G0400491, MC_U147585827, MC_UU_12011/2, MC_UP_A620_1015] Funding Source: UKRI

向作者/读者索取更多资源

Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. Methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the safety of anti-OA treatments in patients with T2DM. Results: T2DM has a pathogenic effect on OA through 2 major pathways involving oxidative stress and low-grade chronic inflammation resulting from chronic hyperglycemia and insulin resistance. T2DM is a risk factor for OA progression and has a negative impact on arthroplasty outcomes. Evidence is mounting for safety concerns with some of the most frequently prescribed anti-OA medications, including paracetamol, non steroidal anti-inflammatory drugs, and corticosteroid injections, while other anti-OA medications may be safely prescribed in OA patients with T2DM, such as glucosamine and intra-articular hyaluronic acid. Conclusions: Future research is needed to better understand whether diabetes control and prevention can modulate OA occurrence and progression. The selection of therapy to treat OA symptoms in patients with T2DM may require careful consideration of the evidence based to avoid untoward safety issues. (C) 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据